ERO1A and familial pancreatic carcinoma: Consistent with this concept, our data confirmed that ERO1α-deficient pancreatic cancer cells displayed negligible ability to form tumors in vivo, thus implicating ERO1α as a potential novel target for cancer therapy in human patients.